Stock Pick

Here’s an ASX 200 share that I think could beat CSL in 2026

Written by

openjargon

in

Six smiling health workers pose for a selfie.

CSL Ltd (ASX: CSL) shares have dropped another 5.81% in lunchtime trade on Thursday as the biotech’s sharp sell-off continues for another day. 

At the time of writing, the shares are trading at an eight-year low of $153.95 a piece and are now 39.93% lower over the year. 

CSL shares have crashed by more than 14% this week alone after the ASX biotech company released a soft half-year result yesterday, following a shock CEO exit on Tuesday.

Analysts have been pretty positive on CSL shares for some time, with many tipping an extraordinary comeback this year. But I think the company’s latest update shows we may be further away from a recovery than the market realised.

Here’s another ASX healthcare stock I’d look at instead. And I think its shares could outperform CSL over the next 12 months.

The ASX share that could beat CSL

ResMed Inc (ASX: RMD) develops, manufactures, and distributes medical devices and provides cloud-based software to diagnose and treat a range of sleep and respiratory disorders. 

At the time of writing, its shares are down 2.27% for the day at $35.955 and 4.25% lower over the year. There has been no news out of the company this week to explain the drop, so it’s likely a flurry of investors selling up.

Late last month, ResMed posted a strong quarterly result for the period ended 31 December. The company announced an 11% year-on-year increase in revenue and an 18% increase in income from operations. 

ResMed also revealed that for the second half of FY26, it plans to increase investment in digital health solutions and innovation, aiming to expand global access to home-based care. The company also said it plans to scale up its AI-enabled technology, following recent FDA clearance for its Smart Comfort device.

I think there is an incredible amount of potential ahead for the stock this year. And analysts seem to be bullish about its outlook, too. 

Here’s what analysts expect from ResMed shares this year

Data shows that 21 out of 30 analysts have a buy or strong buy rating on ResMed shares. The maximum target price is $53.82 a piece, which implies a potential 50.35% upside at the time of writing.

Morgans has a buy rating on ResMed shares and said it thinks that recent share price weakness is unjustified given the company’s sound fundamentals.

Ord Minnett is also incredibly positive about the company’s outlook this year. The broker has a buy rating on the shares and said it has a “strongly positive view on ResMed” following its latest results.

The post Here’s an ASX 200 share that I think could beat CSL in 2026 appeared first on The Motley Fool Australia.

Should you invest $1,000 in ResMed Inc. right now?

Before you buy ResMed Inc. shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ResMed Inc. wasn’t one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys…

See the 5 Stocks

* Returns as of 1 Jan 2026

.custom-cta-button p {
margin-bottom: 0 !important;
}

More reading

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More posts